Federal Organ Donation Campaign Offers Model for Clinical Trials Awareness Effort, Says New White Paper
The federal government’s 1990s “Share your life. Share your decision.” awareness campaign capitalized on endorsements from the likes of Michael Jordan to increase organ donor registrations nationwide.
Court Ruling Could Limit Abuse of 340B Drug Pricing Program
The 340B drug pricing program may soon be one step closer to reclaiming its original intent: allowing hospitals to provide care and necessary medical therapies for underserved patients.
New AfPA Video Considers Access Barriers to Hepatitis C Cures
Since 2013 a new series of medications has offered patients with hepatitis C something radical – a 90 to 99 percent cure rate.
U.S. Senators to CMS: Defer to FDA on Biosimilar Billing Code Issue
A bipartisan group of 20 United States senators have a message for the Centers for Medicare and Medicaid Services: Wait to finalize reimbursement coding policy for biosimilars.
IfPA Releases New Policy Brief: “Improving Patient Access to Immuno-Oncology Therapies”
Immuno-oncology therapies engage the body’s immune system in fighting off cancer, offering some patients unprecedented results.
“America Starts Talking” Encourages Dialogue on Rx Opioid Safety
A new initiative has an important message for pain patients: Every second counts after accidental opioid overdoses, so be prepared.
IfPA Releases “Protecting Premature Infants from Infectious Diseases” Policy Brief
Infectious diseases can pose a threat to all infants, but particularly those born prematurely.
Lawmakers Propose Incentives for Developing Infant Therapies
Pediatric populations historically suffer from a dearth of medical therapies; few new medications are tested on and approved specifically for infants and young children.
Will Recommendation Against COPD Screening Undermine Early Diagnosis?
Screening questionnaires offers a simple, inexpensive way to proactively identify and educate patients at risk for COPD (chronic obstructive pulmonary disease).
Billing Code Proposal Raises Patient Safety Concerns
J-Codes, the billing codes used for medical therapies and procedures, could impact how well physicians and health care systems can monitor patient responses to biological medicines as more biosimilars enter the U.S. market.
